BioSante Pharmaceuticals, Baudette, received a letter from Nasdaq informing BioSante that, since the merger with ANIP Acquisition Co. earlier this week, BioSante was required to meet the initial listing criteria for the Nasdaq Global Market. BioSante did not meet the minimum $4 bid price requirement for initial listings and Nasdaq decided to delist BioSante's securities. BioSante intends to appeal the decision.